

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1p_wp087 (Report 1)

Request ID: cder_mpl1p_wp087

Request Description: In this report we examined dosage of stimulant medications approved for treatment of attention-deficit/hyperactivity disorder (ADHD) in the Sentinel Distributed Database (SDD). This is part one of a four-part report series examining dosage during the pre-COVID (coronavirus disease 2019) pandemic through post-COVID pandemic period. Time periods include: overall (report one; January 1, 2017 to March 31, 2023), pre-pandemic (report two; April 1, 2018 to March 31, 2020), pandemic (report three; April 1, 2020 to March 31, 2022), and post-pandemic (report four; April 1, 2022 to March 31, 2023).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, QRP version 13.1.1

Data Source: We distributed this request to eight Sentinel Data Partners (DPs) on May 23, 2024. The study period for this report included data from January 1, 2017 through March 31, 2023. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: Using the SDD, we separately identified the following cohorts of individuals who initiated each specific ADHD stimulant medication with a minimum of seven days' supply, based on age on the index date: 1) 5 years and older; 2) 18 years and older; 3) 5-17 years; 4) 18-25 years; 5) 26-44 years; 6) 45-64 years; and 7) 65 years and older. The earliest date of dispensing of the exposure drug, with no dispensing of the drug in the 365 days prior, served as the index date.

Exposures of Interest: The exposures of interest were ADHD stimulant medications prescribed in an outpatient setting with a minimum of seven days' supply, identified using National Drug Codes (NDCs). The specific ADHD stimulant medications of interest were: amphetamine/dextroamphetamine combination products, amphetamine/dextroamphetamine immediate release combination products, amphetamine/dextroamphetamine extended release combination products, lisdexamfetamine extended release, methylphenidate, methylphenidate immediate release, and methylphenidate extended release. Please see Appendix B for a list brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We required patients be five years of age and older and to be enrolled in health plans with both medical and drug coverage for at least 365 days prior to the index exposure, during which gaps in coverage of up to 45 days were allowed and treated as continuous enrollment. The 365 days before the index exposure was an exposure washout period (i.e., no dispensed prescription of the exposure of interest).

Episode Creation: We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 30 days apart. Episodes were censored at the earliest occurrence of disenrollment, death, end of the data provided by each Data Partner, the end of the query period, or end of days' supply of the exposure drug.

Dose Metrics: The following dose metrics were reported: average filled daily dose (AFDD) in each patient's first treatment episode and mean current filled daily dose (CFDD) across all dispensings in all treatment episodes.

During each patient's first treatment episode, AFDD was calculated as the product of medication strength and amount supplied divided by the days' supply for each dispensing, averaged across all dispensings. For each patient, CFDD was calculated as the product of medication strength and amount supplied divided by the days' supply for each dispensing, averaged across all dispensings in all treatment episodes. Dispensings with greater than 100 days of supply or greater than 500 units of supply were excluded from all dose calculations.

Patients were grouped into five categories based on their AFDD and CFDD values. The AFDD and CFDD categories for each exposure of interest were: 1) amphetamine/dextroamphetamine combination products: ≤ 20 mg per day, $>20 - 40$ mg per day, $>40 - 60$ mg per day, $>60 - 200$ mg per day, and >200 mg per day; 2) lisdexamfetamine: ≤ 30 mg per day, $>30 - 50$ mg per day, $>50 - 70$ mg per day, $>70 - 200$ mg per day, and >200 mg per day; and 3) methylphenidate: ≤ 20 mg per day, $>20 - 40$ mg per day, $>40 - 60$ mg per day, $>60 - 200$ mg per day, and >200 mg per day.

Please refer to Appendices C through E for the specifications of parameters used in this request and the design diagram.

Overview for Request: cder_mpl1p_wp087 (Report 1)

Disclaimer: Due to the large number of analyses, and to improve efficiency and reduce runtime at the Data Partners, we first created a frozen dataset. The frozen data included the complete claims history of individuals who had a qualifying dispensing of any stimulant, non-stimulant, or C-II opioid drug classes during the study period. As a result, the total counts in the frozen dataset represent only individuals with a qualifying dispensing of drugs of interest and **do not** reflect the entire population of individuals enrolled in the datasets. Because the attrition tables would not accurately represent the full volume of enrollees in the datasets, we did not include attrition tables in this report.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinel-system.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary (CIDA)</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1</u>	Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023
<u>Table 2</u>	Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 23, 2024)
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	Specifications Defining Parameters for this Request
<u>Appendix D</u>	Specifications Defining Stockpiling Parameters Used for this Request
<u>Appendix E</u>	Design Diagram for this Request

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 5+ Years)</i>	905,820	622,280	68.7%	229,154	25.3%	50,374	5.6%	*****	*****	*****	*****	0.1	480.0	20.6	13.0
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 5+ Years)</i>	673,624	447,793	66.5%	169,844	25.2%	51,563	7.7%	*****	*****	*****	*****	0.1	480.0	21.9	15.0
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 5+ Years)</i>	576,872	413,009	71.6%	147,991	25.7%	15,407	2.7%	*****	*****	*****	*****	0.1	300.0	18.9	9.9
<i>Lisdexamfetamine, Extended Release (Patients of Age 5+ Years)</i>	441,633	245,710	55.6%	143,033	32.4%	52,198	11.8%	*****	*****	*****	*****	0.0	300.0	33.6	15.0

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Methylphenidate Single-entity Products, Any (Patients of Age 5+ Years)</i>	563,344	326,189	57.9%	188,350	33.4%	41,825	7.4%	6,966	1.2%	14	0.0%	0.0	300.0	23.1	13.6
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 5+ Years)</i>	326,007	261,943	80.3%	50,116	15.4%	12,668	3.9%	*****	*****	*****	*****	0.4	300.0	16.9	13.2
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 5+ Years)</i>	373,779	164,738	44.1%	163,204	43.7%	38,237	10.2%	*****	*****	*****	*****	0.0	300.0	27.1	13.2
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 5-17 Years)</i>	166,814	148,453	89.0%	17,181	10.3%	1,126	0.7%	*****	*****	*****	*****	0.1	260.0	13.2	7.9

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 5-17 Years)</i>	84,290	76,711	91.0%	6,685	7.9%	833	1.0%	*****	*****	*****	*****	0.5	300.0	12.1	9.2
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 5-17 Years)</i>	133,822	116,998	87.4%	16,085	12.0%	*****	*****	*****	*****	*****	*****	0.1	300.0	13.8	7.5
<i>Lisdexamfetamine, Extended Release (Patients of Age 5-17 Years)</i>	134,628	101,157	75.1%	27,980	20.8%	5,435	4.0%	56	0.0%	0	0.0%	0.0	165.0	26.3	12.6
<i>Methylphenidate Single-entity Products, Any (Patients of Age 5- 17 Years)</i>	227,516	133,809	58.8%	79,441	34.9%	12,203	5.4%	*****	*****	*****	*****	0.0	270.0	21.9	11.8

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 5-17 Years)</i>	94,397	88,540	93.8%	5,179	5.5%	618	0.7%	60	0.1%	0	0.0%	0.4	180.0	11.1	8.0
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 5-17 Years)</i>	204,157	103,808	50.8%	83,622	41.0%	14,183	6.9%	*****	*****	*****	*****	0.0	270.0	24.5	11.7
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 18-25 Years)</i>	181,442	130,396	71.9%	45,004	24.8%	5,724	3.2%	318	0.2%	0	0.0%	0.2	150.0	19.7	10.8
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 18-25 Years)</i>	132,572	94,760	71.5%	31,619	23.9%	5,833	4.4%	360	0.3%	0	0.0%	0.2	150.0	20.1	12.7

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 18-25 Years)</i>	117,006	86,835	74.2%	28,566	24.4%	1,584	1.4%	21	0.0%	0	0.0%	0.3	120.0	18.7	8.3
<i>Lisdexamfetamine, Extended Release (Patients of Age 18-25 Years)</i>	88,118	48,113	54.6%	31,616	35.9%	8,293	9.4%	96	0.1%	0	0.0%	1.0	187.5	34.1	13.5
<i>Methylphenidate Single-entity Products, Any (Patients of Age 18-25 Years)</i>	74,287	35,879	48.3%	30,562	41.1%	6,684	9.0%	1,162	1.6%	0	0.0%	0.0	189.0	25.9	13.5
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 18-25 Years)</i>	38,054	29,869	78.5%	6,929	18.2%	1,150	3.0%	106	0.3%	0	0.0%	0.8	180.0	18.3	12.1

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 18-25 Years)</i>	54,864	19,645	35.8%	27,061	49.3%	6,808	12.4%	1,350	2.5%	0	0.0%	0.0	189.0	29.5	13.4
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 26-44 Years)</i>	335,577	207,782	61.9%	101,948	30.4%	23,967	7.1%	*****	*****	*****	*****	0.1	300.0	22.8	13.4
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 26-44 Years)</i>	268,384	163,654	61.0%	78,081	29.1%	24,572	9.2%	*****	*****	*****	*****	0.1	300.0	23.8	15.2
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 26-44 Years)</i>	210,155	137,963	65.6%	64,966	30.9%	7,057	3.4%	169	0.1%	0	0.0%	0.5	150.0	20.6	10.0

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Lisdexamfetamine, Extended Release (Patients of Age 26-44 Years)</i>	142,649	63,449	44.5%	55,477	38.9%	23,436	16.4%	*****	*****	*****	*****	1.0	210.0	37.6	14.9
<i>Methylphenidate Single-entity Products, Any (Patients of Age 26-44 Years)</i>	107,080	50,736	47.4%	42,632	39.8%	11,843	11.1%	*****	*****	*****	*****	0.4	300.0	26.8	14.5
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 26-44 Years)</i>	62,762	42,540	67.8%	15,647	24.9%	4,229	6.7%	*****	*****	*****	*****	0.4	247.9	21.9	14.4
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 26-44 Years)</i>	68,250	23,425	34.3%	32,734	48.0%	10,066	14.7%	*****	*****	*****	*****	1.0	300.0	30.4	14.1

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 45-64 Years)</i>	164,410	96,300	58.6%	51,604	31.4%	15,204	9.2%	*****	*****	*****	*****	0.5	383.0	24.3	14.7
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 45-64 Years)</i>	136,487	78,298	57.4%	41,049	30.1%	15,680	11.5%	*****	*****	*****	*****	0.5	383.0	25.6	16.3
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 45-64 Years)</i>	92,191	55,537	60.2%	31,649	34.3%	4,828	5.2%	*****	*****	*****	*****	0.5	288.5	22.2	11.4
<i>Lisdexamfetamine, Extended Release (Patients of Age 45-64 Years)</i>	68,907	29,558	42.9%	25,701	37.3%	13,444	19.5%	204	0.3%	0	0.0%	0.8	140.0	38.7	15.8

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Methylphenidate Single-entity Products, Any (Patients of Age 45-64 Years)</i>	76,175	40,893	53.7%	25,555	33.5%	8,292	10.9%	*****	*****	*****	*****	0.5	240.0	25.7	15.7
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 45-64 Years)</i>	55,334	37,348	67.5%	13,294	24.0%	4,218	7.6%	*****	*****	*****	*****	0.5	240.0	22.2	15.5
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 45-64 Years)</i>	36,112	12,400	34.3%	16,421	45.5%	5,930	16.4%	*****	*****	*****	*****	1.8	216.0	31.6	15.2
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 65+ Years)</i>	64,156	43,870	68.4%	15,072	23.5%	4,738	7.4%	*****	*****	*****	*****	0.7	480.0	21.5	15.2

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 65+ Years)</i>	57,026	37,905	66.5%	13,592	23.8%	5,040	8.8%	*****	*****	*****	*****	0.7	480.0	22.6	16.2
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 65+ Years)</i>	27,223	18,009	66.2%	7,797	28.6%	1,327	4.9%	90	0.3%	0	0.0%	1.4	200.0	20.8	12.4
<i>Lisdexamfetamine, Extended Release (Patients of Age 65+ Years)</i>	10,284	5,025	48.9%	3,233	31.4%	1,972	19.2%	*****	*****	*****	*****	5.0	300.0	37.3	17.8
<i>Methylphenidate Single-entity Products, Any (Patients of Age 65+ Years)</i>	81,290	66,342	81.6%	11,303	13.9%	3,134	3.9%	*****	*****	*****	*****	0.5	300.0	16.3	13.4

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 65+ Years)</i>	77,393	65,202	84.2%	9,350	12.1%	2,537	3.3%	*****	*****	*****	*****	0.5	300.0	15.5	12.9
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 65+ Years)</i>	12,259	6,049	49.3%	4,284	34.9%	1,545	12.6%	*****	*****	*****	*****	3.0	300.0	28.6	16.3
<i>Amphetamine/Dextro amphetamine Combination Products, Any (Patients of Age 18+ Years)</i>	742,089	476,279	64.2%	212,547	28.6%	49,303	6.6%	*****	*****	*****	*****	0.1	480.0	22.3	13.4
<i>Amphetamine/Dextro amphetamine Combination Products, Immediate Release (Patients of Age 18+ Years)</i>	591,505	372,891	63.0%	163,471	27.6%	50,777	8.6%	*****	*****	*****	*****	0.1	480.0	23.3	15.2

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
<i>Amphetamine/Dextro amphetamine Combination Products, Extended Release (Patients of Age 18+ Years)</i>	444,811	297,343	66.8%	132,312	29.7%	14,701	3.3%	*****	*****	*****	*****	0.3	288.5	20.4	10.1
<i>Lisdexamfetamine, Extended Release (Patients of Age 18+ Years)</i>	308,677	145,600	47.2%	115,555	37.4%	46,885	15.2%	*****	*****	*****	*****	0.8	300.0	36.8	14.9
<i>Methylphenidate Single-entity Products, Any (Patients of Age 18+ Years)</i>	337,714	193,281	57.2%	109,676	32.5%	29,811	8.8%	4,933	1.5%	13	0.0%	0.0	300.0	23.8	14.6
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 18+ Years)</i>	232,757	174,416	74.9%	45,053	19.4%	12,066	5.2%	*****	*****	*****	*****	0.4	300.0	19.2	14.1

Table 1. Summary of Average Filled Daily Dose (AFDD) in Each Initiator's First Valid Episode for Exposures of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Average Filled Daily Dose in First Treatment Episode ¹										Distribution of Average Filled Daily Dose			
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5					
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
Methylphenidate	171,008	61,385	35.9%	80,282	46.9%	24,250	14.2%	*****	*****	*****	*****	0.0	300.0	30.2	14.3

Single-entity Products,
Extended Release
(Patients of Age 18+
Years)

¹Categories of Amphetamine/Dextroamphetamine Combination Products: <=20 mg per day, >20 - 40 mg per day, >40 -60 mg per day, >60-200 mg per day, and >200 mg per day;
Categories of Lisdexamfetamine Products: <=30 mg per day, >30 - 50 mg per day, >50 -70 mg per day, >70-200 mg per day, and >200 mg per day;
Categories of Methylphenidate Products: <=20 mg per day, >20 - 40 mg per day, >40 -60 mg per day, >60-200 mg per day, and >200 mg per day
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 5+ Years)</i>	905,820	559,165	61.7%	277,303	30.6%	63,370	7.0%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 5+ Years)</i>	673,624	420,319	62.4%	187,226	27.8%	60,074	8.9%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 5+ Years)</i>	576,872	390,615	67.7%	168,055	29.1%	17,562	3.0%	*****	*****	*****	*****
<i>Lisdexamfetamine, Extended Release (Patients of Age 5+ Years)</i>	441,633	226,634	51.3%	153,626	34.8%	59,556	13.5%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Any (Patients of Age 5+ Years)</i>	563,344	291,948	51.8%	208,294	37.0%	53,243	9.5%	9,843	1.7%	16	0.0%
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 5+ Years)</i>	326,007	253,999	77.9%	55,987	17.2%	14,411	4.4%	1,599	0.5%	11	0.0%
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 5+ Years)</i>	373,779	143,025	38.3%	175,095	46.8%	46,145	12.3%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 5-17 Years)</i>	166,814	140,506	84.2%	24,601	14.7%	1,611	1.0%	*****	*****	*****	*****

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 5-17 Years)</i>	84,290	74,973	88.9%	8,222	9.8%	1,014	1.2%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 5-17 Years)</i>	133,822	112,677	84.2%	20,198	15.1%	924	0.7%	*****	*****	*****	*****
<i>Lisdexamfetamine, Extended Release (Patients of Age 5-17 Years)</i>	134,628	94,217	70.0%	33,370	24.8%	6,815	5.1%	226	0.2%	0	0.0%
<i>Methylphenidate Single-entity Products, Any (Patients of Age 5-17 Years)</i>	227,516	113,572	49.9%	93,173	41.0%	17,675	7.8%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 5-17 Years)</i>	94,397	86,700	91.8%	6,774	7.2%	837	0.9%	86	0.1%	0	0.0%
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 5-17 Years)</i>	204,157	87,531	42.9%	94,141	46.1%	19,011	9.3%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 18-25 Years)</i>	181,442	115,179	63.5%	57,701	31.8%	8,023	4.4%	539	0.3%	0	0.0%
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 18-25 Years)</i>	132,572	88,898	67.1%	35,977	27.1%	7,176	5.4%	521	0.4%	0	0.0%

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 18-25 Years)</i>	117,006	81,906	70.0%	33,154	28.3%	1,899	1.6%	47	0.0%	0	0.0%
<i>Lisdexamfetamine, Extended Release (Patients of Age 18-25 Years)</i>	88,118	44,174	50.1%	34,044	38.6%	9,590	10.9%	310	0.4%	0	0.0%
<i>Methylphenidate Single-entity Products, Any (Patients of Age 18-25 Years)</i>	74,287	32,118	43.2%	32,108	43.2%	8,401	11.3%	1,660	2.2%	0	0.0%
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 18-25 Years)</i>	38,054	28,814	75.7%	7,799	20.5%	1,304	3.4%	137	0.4%	0	0.0%
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 18-25 Years)</i>	54,864	17,833	32.5%	27,569	50.2%	7,846	14.3%	1,616	2.9%	0	0.0%
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 26-44 Years)</i>	335,577	182,611	54.4%	119,994	35.8%	30,115	9.0%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 26-44 Years)</i>	268,384	152,760	56.9%	84,301	31.4%	28,476	10.6%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 26-44 Years)</i>	210,155	129,961	61.8%	71,927	34.2%	8,010	3.8%	257	0.1%	0	0.0%

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Lisdexamfetamine, Extended Release (Patients of Age 26-44 Years)</i>	142,649	58,597	41.1%	57,120	40.0%	26,185	18.4%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Any (Patients of Age 26-44 Years)</i>	107,080	45,905	42.9%	44,406	41.5%	14,137	13.2%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 26-44 Years)</i>	62,762	40,784	65.0%	16,796	26.8%	4,729	7.5%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 26-44 Years)</i>	68,250	21,555	31.6%	33,041	48.4%	11,226	16.4%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 45-64 Years)</i>	164,410	86,129	52.4%	58,159	35.4%	18,257	11.1%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 45-64 Years)</i>	136,487	72,566	53.2%	44,135	32.3%	17,843	13.1%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 45-64 Years)</i>	92,191	52,098	56.5%	34,514	37.4%	5,364	5.8%	*****	*****	*****	*****
<i>Lisdexamfetamine, Extended Release (Patients of Age 45-64 Years)</i>	68,907	27,287	39.6%	26,256	38.1%	14,896	21.6%	468	0.7%	0	0.0%

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Methylphenidate Single-entity Products, Any (Patients of Age 45-64 Years)</i>	76,175	37,945	49.8%	26,678	35.0%	9,642	12.7%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 45-64 Years)</i>	55,334	35,772	64.6%	14,220	25.7%	4,759	8.6%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 45-64 Years)</i>	36,112	11,449	31.7%	16,520	45.7%	6,535	18.1%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 65+ Years)</i>	64,156	41,294	64.4%	16,865	26.3%	5,390	8.4%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 65+ Years)</i>	57,026	35,944	63.0%	14,886	26.1%	5,601	9.8%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 65+ Years)</i>	27,223	17,315	63.6%	8,361	30.7%	1,445	5.3%	102	0.4%	0	0.0%
<i>Lisdexamfetamine, Extended Release (Patients of Age 65+ Years)</i>	10,284	4,797	46.6%	3,273	31.8%	2,122	20.6%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Any (Patients of Age 65+ Years)</i>	81,290	64,516	79.4%	12,603	15.5%	3,548	4.4%	*****	*****	*****	*****

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 65+ Years)</i>	77,393	63,739	82.4%	10,470	13.5%	2,829	3.7%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 65+ Years)</i>	12,259	5,751	46.9%	4,441	36.2%	1,638	13.4%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Any (Patients of Age 18+ Years)</i>	742,089	421,924	56.9%	252,523	34.0%	61,753	8.3%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Immediate Release (Patients of Age 18+ Years)</i>	591,505	347,575	58.8%	178,956	30.3%	59,050	10.0%	*****	*****	*****	*****
<i>Amphetamine/Dextroamphetamine Combination Products, Extended Release (Patients of Age 18+ Years)</i>	444,811	279,712	62.9%	147,829	33.2%	16,651	3.7%	*****	*****	*****	*****
<i>Lisdexamfetamine, Extended Release (Patients of Age 18+ Years)</i>	308,677	133,957	43.4%	120,386	39.0%	52,733	17.1%	*****	*****	*****	*****
<i>Methylphenidate Single-entity Products, Any (Patients of Age 18+ Years)</i>	337,714	179,672	53.2%	115,581	34.2%	35,674	10.6%	6,773	2.0%	14	0.0%
<i>Methylphenidate Single-entity Products, Immediate Release (Patients of Age 18+ Years)</i>	232,757	168,439	72.4%	49,214	21.1%	13,577	5.8%	1,516	0.7%	11	0.0%

Table 2. Distribution of Mean Current Filled Daily Dose (CFDD) Categories for Active Pharmaceutical Ingredients (APIs) across All Dispensings in All API Treatment Episodes of Interest in the Sentinel Distributed Database from January 1, 2017 to March 31, 2023

	Total Number of Patients	Number of Patients by Filled Daily Dose ¹									
		Dose Group 1		Dose Group 2		Dose Group 3		Dose Group 4		Dose Group 5	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Methylphenidate Single-entity Products, Extended Release (Patients of Age 18+ Years)</i>	171,008	56,318	32.9%	81,437	47.6%	27,201	15.9%	*****	*****	*****	*****

¹Categories of Amphetamine/Dextroamphetamine Combination Products: <=20 mg per day, >20 - 40 mg per day, >40 -60 mg per day, >60-200 mg per day, and >200 mg per day;

Categories of Lisdexamfetamine Products: <=30 mg per day, >30 - 50 mg per day, >50 -70 mg per day, >70-200 mg per day, and >200 mg per day;

Categories of Methylphenidate Products: <=20 mg per day, >20 - 40 mg per day, >40 -60 mg per day, >60-200 mg per day, and >200 mg per day

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 23, 2024)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	03/31/2023
DP02	01/01/2007	03/31/2023
DP03	01/01/2000	03/31/2023
DP04	01/01/2006	03/31/2023
DP05	01/01/2000	03/31/2023
DP06	01/01/2008	03/31/2023
DP07	01/01/2004	03/31/2023
DP08	01/01/2008	03/31/2023

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Amphetamine/Dextroamphetamine Combination Products Immediate Release	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
Amphetamine/Dextroamphetamine Combination Products Extended Release	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mydayis
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
Lisdexamfetamine Extended Release	
lisdexamfetamine dimesylate	Vyvanse
lisdexamfetamine dimesylate	lisdexamfetamine
Methylphenidate Single-entity Products Immediate Release	
methylphenidate HCl	Methylin
methylphenidate HCl	Ritalin
methylphenidate HCl	methylphenidate HCl
Methylphenidate Single-entity Products Extended Release	
methylphenidate	Cotempla XR-ODT
methylphenidate	Daytrana
methylphenidate	methylphenidate
methylphenidate HCl	Adhansia XR
methylphenidate HCl	Aptensio XR
methylphenidate HCl	Concerta
methylphenidate HCl	Jornay PM
methylphenidate HCl	Metadate CD
methylphenidate HCl	Metadate ER
methylphenidate HCl	QuilliChew ER
methylphenidate HCl	Quillivant XR
methylphenidate HCl	Relexxii
methylphenidate HCl	Ritalin LA
methylphenidate HCl	methylphenidate HCl

Appendix C. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool v13.1.1 to investigate the use of Attention-Deficit/Hyperactivity Disorder Medications within pre- and post-pandemic time periods among prespecified age groups in the Sentinel Distributed Database (SDD).

1. R01: Type 5 (Overall study period)
2. R02: Type 5 (Pre-pandemic study period)
3. R03: Type 5 (Pandemic study period)
4. R04: Type 5 (Post-pandemic study period)

Query period: January 1, 2017 - March 31, 2023 (overall)
 April 1, 2018 - March 31, 2020 (pre-pandemic)
 April 1, 2020 - March 31, 2022 (pandemic)
 April 1, 2022 - March 31, 2023 (latest available)

Coverage requirement: Medical & Drug Coverage

Pre-index enrollment requirement: 365 days

Post-index requirement: N/A

Enrollment gap: 45 days

Age groups: See below in the Age Group column

Stratifications: Age groups
 Census bureau (CB) region

Censor output categorization: -

Restrictions: None

Distribution of index-defining codes: No

*Reclassify outpatient (AV), emergency department (ED), and other ambulatory (OA) encounters that occur during an inpatient stay as inpatient (IP) encounters. Do not reclassify if an encounter occurs on the day of admission (ADate).

Envelope macro:

Freeze data: No

Stockpiling See stockpiling tab

Features: Run type 2 cohort off of Type 5 cohort of corresponding query period to ensure identical patients captured
 Carry forward other reporting features from cder_mpl1p_wp085
 Output the number of patients who had a mean/median current filled daily dose across all their dispensings within a user defined range
 Most frequent utilization (MFU) output and reporting
 Compute t-statistic and Z-statistic for comparisons between proportions between pre-pandemic and pandemic query periods, and report p-value

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
Overall	22	5+ years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	23	5+ years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	24	5+ years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Episode at Evidence of:	Daily Dose Summary (Mean) Category
Overall	25	5+ years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+
	26	5+ years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	27	5+ years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
Overall	28	5+ years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
5-17 Years	29	5-17 years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	30	5-17 years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
5-17 Years	31	5-17 years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	32	5-17 Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+
	33	5-17 years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
5-17 Years	34	5-17 years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	35	5-17 years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
18-25 Years	36	18-25 Years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
18-25 Years	37	18-25 Years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	38	18-25 Years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	39	18-25 Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
18-25 Years	40	18-25 Years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	41	18-25 Years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	42	18-25 Years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
26-44 Years	43	26-44 Years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	44	26-44 Years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	45	26-44 Years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure														
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if		Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
						Washout Includes Dispensings	Treatment								
26-44 Years	46	26-44 Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+	
	47	26-44 Years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+	
	48	26-44 Years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+	

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
26-44 Years	49	26-44 Years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
45-64 Years	50	45-64 Years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	51	45-64 Years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

Exposure														
Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category	
45-64 Years	52	45-64 Years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	53	45-64 Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+
	54	45-64 Years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
45-64 Years	55	45-64 Years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	56	45-64 Years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
65+ Years	57	65+ Years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure	Exclude Evidence of Days Supply if	Treatment Episode	Treatment Episode	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to	Censor Treatment Episode at	Current Filled
					Washout Period	Washout Includes Dispensings	Gap	Extension				Attach to Dispensings	Evidence of:	Daily Dose Summary (Mean) Category
65+ Years	58	65+ Years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	59	65+ Years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	60	65+ Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
65+ Years	61	65+ Years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	62	65+ Years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	63	65+ Years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

Exposure														
Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category	
18+ Years	64	18+ Years	Amphetamine/Dextroamphetamine Combination Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	65	18+ Years	Amphetamine/Dextroamphetamine Combination Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	66	18+ Years	Amphetamine/Dextroamphetamine Combination Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request


	Exposure													
	Scenario	Age Restriction	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Washout Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category
18+ Years	67	18+ Years	Lisdexamfetamine, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-30 31-50 51-70 71+
	68	18+ Years	Methylphenidate Single-entity Products, Any	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	69	18+ Years	Methylphenidate Single-entity Products, Immediate Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+

Appendix C. Specifications Defining Parameters for this Request

	Exposure													
				Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Includes Dispensings	Treatment Episode Gap	Treatment Episode Extension	Care Setting	Principal Diagnosis Position	Create Baseline Table?	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Current Filled Daily Dose Summary (Mean) Category	
	Scenario	Age Restriction	Index Exposure	Cohort Definition										
18+ Years	70	18+ Years	Methylphenidate Single-entity Products, Extended Release	*Include all valid exposure episodes during query period; --only the first valid exposure episode's incidence is assessed using washout criteria	365 days	*Washout lookback period should search for evidence of days supply;	30 days	None	Outpatient dispensing	N/A	No	N/A	*Death; *DP end date; *Query end date; *Enrollment end date; *Episode end date	1-20 21-40 41-60 61+
	National Drug Codes (NDCs) are checked against First Data Bank's FDB MedKnowledge®.													
	N/A: Not applicable													

Appendix D. Specifications Defining Stockpiling Parameters Used for this Request

Stockpiling					
Stockpiling Group	Same Day Dispensing Processing for Days Supplied	Same Day Dispensing Processing for	Range of Allowable Days Supplied Values	Range of Allowable Amount Supplied Values	Overlap Percentage*
Use drug class for the stockpiling except when calculating average daily dose by active ingredient. For calculating average daily dose by active ingredient, use generic name for stockpiling	*Maximum for both exposure cohorts and active pharmaceutical ingredients (API) cohorts (to allow for cumulative filled daily dose (CFDD) calculations)	*Adds all	Exposure cohorts: 7 days - HIGH API cohorts: 7-100	Exposure cohorts: Does not consider amount supplied values of 0 or less API cohorts: 0<-500	Default: No truncation will occur and any overlap of supply between dispensing will be corrected by pushing overlapping days supplied forward



Appendix E. Design Diagram for this Request

